{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:50:44Z","timestamp":1769161844188,"version":"3.49.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/inf.0b013e3182a74233","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T12:27:35Z","timestamp":1375360055000},"page":"e451-e455","source":"Crossref","is-referenced-by-count":20,"title":["Voriconazole Prophylaxis in Children With Cancer"],"prefix":"10.1097","volume":"32","author":[{"given":"Gabriela M.","family":"Maron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall T.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry L.","family":"Shenep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkn027","article-title":"Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.","volume":"61","author":"Cornely","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.24107","article-title":"Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.","volume":"115","author":"Sung","year":"2009","journal-title":"Cancer"},{"key":"R3-14-20210202","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases.","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients.","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transplant"},{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00520-009-0783-3","article-title":"Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.","volume":"19","author":"Mattiuzzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0609.2009.01367.x","article-title":"Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.","volume":"84","author":"Torres","year":"2010","journal-title":"Eur J Haematol"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jinf.2007.07.003","article-title":"A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).","volume":"55","author":"Vehreschild","year":"2007","journal-title":"J Infect"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2009.30","article-title":"Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.","volume":"23","author":"Rubnitz","year":"2009","journal-title":"Leukemia"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of CancerInvasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTCMSG) Consensus Group.","volume":"46","author":"De","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/MPH.0b013e3182331bc7","article-title":"Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.","volume":"33","author":"Mandhaniya","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2011.111","article-title":"Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT.","volume":"47","author":"Molina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/313445","article-title":"Aspergillosis in children with cancer: A 34-year experience.","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/597400","article-title":"Phaeohyphomycosis in a tertiary care cancer center.","volume":"48","author":"Ben-Ami","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1086\/375822","article-title":"Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.","volume":"37","author":"Husain","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R19-14-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diagmicrobio.2006.01.018","article-title":"Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.","volume":"55","author":"Siwek","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R21-14-20210202","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R22-14-20210202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1086\/597615","article-title":"Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.","volume":"199","author":"Lamaris","year":"2009","journal-title":"J Infect Dis"},{"key":"R23-14-20210202","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/JCM.05946-11","article-title":"Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay.","volume":"50","author":"Tortorano","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"suppl 5","key":"R24-14-20210202","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1469-0691.2009.02985.x","article-title":"Current experience in treating invasive zygomycosis with posaconazole.","volume":"15","author":"Cornely","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/TCRM.S3329","article-title":"Posaconazole in the management of refractory invasive fungal infections.","volume":"4","author":"Langner","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: a multicentre survey.","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R27-14-20210202","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-14-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R29-14-20210202","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1399-3062.2007.00210.x","article-title":"Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.","volume":"9","author":"Wingard","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"R30-14-20210202","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","article-title":"Voriconazole.","volume":"25","author":"Jeu","year":"2003","journal-title":"Clin Ther"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-14-20210202","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e3182a74233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:13:14Z","timestamp":1620954794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201312000-00014"}},"subtitle":["Changing Outcomes and Epidemiology of Fungal Infections"],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3182a74233","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}